Headquartered in London and publicly traded on the London Stock Exchange
AIM: POLB
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets.
With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
Reasons to Invest
Experienced team with proven track record
- Highly experienced management team with expertise in trial execution, deal-making, company building, and generating shareholder returns
- Cathal Friel, Co-Founder & Executive Chair – notable successes include co-founding Amryt Pharma plc which was acquired for US$1.48B in 2023, and hVIVO plc
- CEO Jeremy Skillington, PhD, was instrumental in Inflazome’s US$450M+ sale to Roche in 2020
High-value programmes targeting critical unmet medical needs
- POLB 001: Potentially breakthrough oral preventative therapy for cancer immunotherapy-induced CRS with FDA Orphan Drug Designation. POLB 001 has the potential to transform the cancer immunotherapy field, with a market opportunity of <US$10B1. By making cancer immunotherapy treatment safer through the prevention of the life-threatening side effect, CRS, POLB 001 has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
- Oral encapsulated GLP-1 programme: A patient-friendly therapy targeting the growing obesity market using proprietary drug delivery technology. Oral GLP-1 options remain limited yet highly sought after, 65% of patients that discontinued treatment stated they would prefer oral alternatives1 An effective oral GLP-1 could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments.
- Two successful AI-led discovery programmes: Transforming human challenge trial data into potential clinical candidates for RSV and influenza.
Programmes attractive for Pharma partnering
- Cost-effective trials designed to produce high-quality proof of concept human data to accelerate partnering discussions with pharma to maximise value from programmes and generate shareholder returns
- Cancer immunotherapies & GLP-1 are large and fast-growing markets
- Strong IP, potential for protection out to at least 2044 for POLB 001
- Global, exclusive licensed rights for clinical stage assets
- FDA Orphan Drug Designation further validates POLB 001’s scientific rationale and strengthens its commercial appeal for prospective partners
- Team experienced in deal-making
Cash runway into 2027, funding key clinical milestones in oncology & obesity
- Debt free with cash runway into 2027
- Oversubscribed and upsized fundraise in June 2025, due to strong investor demand
- POLB 001 trial in advanced stages of preparation with approved bispecific antibody secured for trial. Interim data expected Summer 2026
- Progressing towards Oral GLP-1 proof of concept trial commencement with topline data expected H1 2026
Upcoming Events
09 Oct
Optimum’s 17th Annual Healthcare Investor Conference
Investor Presentation with Investor Meet Company
29 September 2025
Get in touch with our investor relations team at